Saul J Priceman

Saul J. Priceman is a prominent inventor based in Duarte, California. He has made significant contributions to the field of cancer treatment through his innovative research and development of oncolytic viruses and chimeric antigen receptors. With a total of 5 patents, his work is paving the way for new therapeutic approaches in oncology.

Latest Patents

Among his latest patents, Priceman has developed an oncolytic virus that expresses a CAR T cell target. This oncolytic poxvirus encodes a truncated human CD19 and is utilized in conjunction with a chimeric antigen receptor to treat solid tumors. Another notable patent involves TAG72-targeted chimeric antigen receptor modified T cells, which are designed for the treatment of TAG72-positive tumors, including ovarian cancer and other malignancies.

Career Highlights

Priceman is affiliated with City of Hope, a leading research and treatment center for cancer. His work at this institution has allowed him to focus on groundbreaking research that aims to improve patient outcomes through innovative therapies. His dedication to advancing cancer treatment is evident in his numerous patents and ongoing research efforts.

Collaborations

Throughout his career, Priceman has collaborated with esteemed colleagues such as Stephen J. Forman and Christine E. Brown. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in cancer research.

Conclusion

Saul J. Priceman's contributions to the field of oncology through his innovative patents and research at City of Hope highlight his commitment to improving cancer treatment. His work continues to inspire advancements in medical science and offers hope for patients facing challenging diagnoses.

This text is generated by artificial intelligence and may not be accurate.